Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America

University of Mississippi Medical Center, Jackson, USA.
Clinical Infectious Diseases (Impact Factor: 9.42). 07/2008; 46(12):1801-12. DOI: 10.1086/588300
Source: PubMed

ABSTRACT Evidence-based guidelines for the management of patients with blastomycosis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous management guidelines published in the April 2000 issue of Clinical Infectious Diseases. The guidelines are intended for use by health care providers who care for patients who have blastomycosis. Since 2000, several new antifungal agents have become available, and blastomycosis has been noted more frequently among immunosuppressed patients. New information, based on publications between 2000 and 2006, is incorporated in this guideline document, and recommendations for treating children with blastomycosis have been noted.


Available from: Laurie Proia, May 04, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fungal infections of the central nervous system have manifold presentations and courses that depend largely on both host and organism characteristics. Although subjects with impaired immunity are generally at higher risk for severe disease, several fungal organisms are considered primary pathogens and can also cause disease in otherwise immunocompetent individuals. Herein, we describe the epidemiology, presentation, diagnosis, and management of central nervous system complications of several fungal pathogens.
    Current Infectious Disease Reports 12/2014; 16(12):449. DOI:10.1007/s11908-014-0449-2
  • [Show abstract] [Hide abstract]
    ABSTRACT: Blastomycosis osteomyelitis is a well-known but infrequently encountered complication of infection with the dimorphic mold, Blastomyces dermatitidis. Oftentimes, the diagnosis is unsuspected, resulting in a delay in making the diagnosis. The role of intraoperative consultation in making a rapid diagnosis has not been discussed previously.
    American Journal of Clinical Pathology 11/2014; 142(5):609-16. DOI:10.1309/AJCPG2CFGHZ4URLN · 3.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Knowledge of the currently available antifungal agents, along with clinical, microbiologic and histopathologic methods, can help the medical professional optimally manage skin and nail fungal infections. With regards to treatment of fungal disease of the skin or nail, there are a variety of systemic antifungal agents, including several newer agents that have different formulations, tolerability, adverse effect profiles and spectrum of activity. This review will highlight the clinically important fungal infections of the skin and nail and describe the activity and role of antifungal treatment.
    Expert Review of Anti-infective Therapy 09/2014; 12(11):1-17. DOI:10.1586/14787210.2014.960849 · 2.28 Impact Factor